bullish
AFT Pharmaceuticals - 14% revenue growth despite COVID-19 headwinds
SUMMARY
AFT Pharmaceuticals recently reported its results for H122. Operating revenue grew strongly by 14% year-on-year to NZ$55.5m, despite the impact of COVID-19 across the business (extended lockdowns in Australia and delayed launches in international markets were the biggest COVID-related headwinds). Reported group operating profit was NZ$5.5m compared to NZ$2.4m in the same period a year ago. Importantly, AFT is continuing to guide for operating profit of NZ$18–23m in FY22.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Edison Investment Research
Leading International Investment Research
Price Chart(Sign Up to Access)
- AFT Pharmaceuticals - 14% revenue growth despite COVID-19 headwinds22 Nov 2021
x